Get the Stockscreener App
2.39
12.77%
-0.35
After Hours:
2.34
-0.05
-2.09%
Lakewood Amedex Biotherapeutics Inc stock is traded at $2.39, with a volume of 219.80K.
It is down -12.77% in the last 24 hours and up +257.78% over the past month.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
See More
Previous Close:
$2.74
Open:
$2.73
24h Volume:
219.80K
Relative Volume:
0.13
Market Cap:
$4.18M
Revenue:
-
Net Income/Loss:
$-4.23M
P/E Ratio:
-2.7159
EPS:
-0.88
Net Cash Flow:
$-1.89M
1W Performance:
-23.89%
1M Performance:
+257.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.3101
$2.82
1-Week Range:
$2.3101
$3.50
52-Week Range:
$0.366
$9.40
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
Name
Lakewood Amedex Biotherapeutics Inc
Sector
Industry
Phone
(941) 225-2515
Address
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
2.39 | 4.80M | 0 | -4.23M | -1.89M | -0.88 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Latest News
Lakewood-Amedex backs reintroduced PASTEUR Act legislation - Investing.com
Lakewood-Amedex supports PASTEUR Act as Nu-3 heads toward Phase 2 - Stock Titan
Price to book forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
Price to sales forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView
Lakewood-Amedex Biotherapeutics Inc. Actuals & Estimates (NASDAQ:LABT) - TradingView
Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat
Price to earnings forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView
Lakewood-Amedex Biotherapeutics (LABT) Q1 2026 earnings summary - Quartr
Lakewood-Amedex Biotherapeutics (LABT) Life Sciences Virtual Investor Forum Summary - Quartr
Lakewood-Amedex names Armstrong as study chair for Phase 2a trial - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers - PR Newswire
Enterprise value to revenue forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView
Price to earnings forward of Lakewood-Amedex Biotherapeutics Inc. – BOATS:LABT - TradingView
Form 13G LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. For: 23 June By Investing.com - Investing.com South Africa
[SCHEDULE 13G] Lakewood-Amedex Biotherapeutics Inc. Passive Investment Disclosure (>5%) - Stock Titan
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin(R) Compounds Being Developed for High-Need Antimicrobial Infections - marketscreener.com
1-for-10 Reverse Split Shrinks Share Count (LABT) Ahead of Nasdaq Re‑listing - Stock Titan
Lakewood-Amedex (LABT) 1-for-10 reverse split takes effect; new CUSIP 51255A201 - Stock Titan
Lakewood-Amedex Biotherapeutics announces new patent in Australia - TipRanks
Lakewood-Amedex receives Australian patent for antimicrobials By Investing.com - Investing.com Nigeria
Lakewood-Amedex receives Australian patent for antimicrobials - Investing.com
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections - Morningstar
Lakewood-Amedex Biotherapeutics, Inc.(NasdaqCM: LABT) added to S&P TMI Index - marketscreener.com
Lakewood-Amedex Biotherapeutics Earnings Date, Reports & Earnings Call - Moomoo
Lakewood-Amedex Biotherapeutics plans 1-for-10 reverse stock split - Investing.com
Lakewood-Amedex Biotherapeutics plans 1-for-10 reverse stock split By Investing.com - Investing.com Nigeria
Lakewood-Amedex (NASDAQ: LABT) plans 1-for-10 reverse stock split - Stock Titan
LABT Stock Soars 50% After Nasdaq Debut – Retail Says $14 Is The Line In The Sand - Stocktwits
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Yahoo Finance
Lakewood-Amedex highlights Nu-3 gel for infected diabetic foot ulcers - Stock Titan
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis $LABT - MarketBeat
Lakewood-Amedex stock falls despite positive Nu-3 manufacturing update - MSN
Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper - TipRanks
Lakewood-Amedex Biotherapeutics(LABT) Stock Options Chain | Quotes & News - Moomoo
Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial - Investing.com Nigeria
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers - GuruFocus
Lakewood-Amedex Biotherapeutics issued two new patents - TipRanks
Lakewood-Amedex receives patents in Australia, New Zealand By Investing.com - Investing.com South Africa
Lakewood-Amedex receives patents in Australia, New Zealand - Investing.com Australia
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):